CIK 0001710072
EWTX Edgewise Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Dec 31, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
3
with a Form 4 at this company
Signals
Open-market buys and sells at Edgewise Therapeutics, Inc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 33Weak | sell 210b5-1 | Russell Alan J Chief Scientific Officer | $2.7M | 100,000 | -87% | - | |
| 31Weak | sell 210b5-1 | Semigran Marc Chief Development Officer | $882k | 29,709 | -82% | - |
Transactions
The last 9 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | Russell Alan J Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +100,000 | $0.18 | $18k | 114,863 | Dec 31, 2024 |
| Dec 30, 2024 | Russell Alan J Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -100,000 | $27.37 | $2.7M | 14,863 | Dec 31, 2024 |
| Dec 30, 2024 | Russell Alan J Chief Scientific Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 1,356,780 | Dec 31, 2024 |
| Dec 24, 2024 | Semigran Marc Chief Development Officer | MOption exercise Common Stock10b5-1 | +29,709 | $8.94 | $266k | 36,425 | Dec 27, 2024 |
| Dec 24, 2024 | Semigran Marc Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -27,980 | $29.66 | $830k | 8,445 | Dec 27, 2024 |
| Dec 24, 2024 | Semigran Marc Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -1,729 | $30.08 | $52k | 6,716 | Dec 27, 2024 |
| Dec 24, 2024 | Semigran Marc Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -29,709 | $0.00 | $0 | 270,291 | Dec 27, 2024 |
| Oct 11, 2024 | Carruthers R Michael Chief Financial Officer | MOption exercise Common Stock | +70,000 | $0.71 | $50k | 76,904 | Oct 16, 2024 |
| Oct 11, 2024 | Carruthers R Michael Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -70,000 | $0.00 | $0 | 127,122 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Carruthers R MichaelChief Financial Officer
- Russell Alan JChief Scientific Officer
- Semigran MarcChief Development Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.